Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An announcement from CareDx ( (CDNA) ) is now available.
CareDx announced its preliminary financial results for the fourth quarter and full year of 2024, highlighting a significant 30% year-over-year revenue growth in the fourth quarter and a full-year revenue projection between $332 million to $333 million. The company anticipates strong growth in 2025 with expected revenue of $370 million, supported by the expansion of its sales and marketing team and continued momentum in kidney surveillance testing. Despite a projected GAAP loss, CareDx achieved positive adjusted EBITDA, indicating operational efficiency and financial health improvements.
More about CareDx
CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients.
YTD Price Performance: 9.80%
Average Trading Volume: 797,435
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.27B
See more insights into CDNA stock on TipRanks’ Stock Analysis page.
